Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Aranesp Prescribers (US)

Articles with lock require a subscription to GLG News | Request a free trial
July 24, 2008
Sorafenib (Bayer) in hepatocellular carcinoma (HCC): already factored in!
Analysis of: Sorafenib in Advanced Hepatocellular Carcinoma | content.nejm.org
Author: GLG Expert Contributor
Sorafenib increases time to progression and median survival in HCC. (World wide a major neoplasm)
July 24, 2008
I know, there is no money in diagnostics, BUT.......
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org
Author: GLG Expert Contributor
Peripheral blood in patients with metastatic non small cell lung cancer (NSCLCA) can determine the presence of EGFR mutations in circulating cancer cells that will reveal sensitivity to TKI's- Erbitux (ImClone & BMS), Tarceva (Genentech) and even Iressa (AZ).
July 24, 2008
Erbitux (BMS/ImClone) in Lung Ca: Finally some meat??
Analysis of: Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy | jco.ascopubs.org
Author: GLG Expert Contributor
Lung cancer patients who have increased gene copies of EGFR do better with Cetuximab than do those who do not.
July 21, 2008
Is Alimta (Lilly) the answer? (What is the question?)
Analysis of: Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Individualizing chemotherapy depending on histology (adenocarcinomas) shows that Alimta/CisPlatin appears to be more convenient and less toxic than its stablemate Gemzar.
July 21, 2008
As if Rituxan (Genentech/Biogen) needed another market?
Analysis of: Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation | content.nejm.org
Author: GLG Expert Contributor
For patients with antibodies that may make renal transplants problematic, Rituxan may make them possible!
July 14, 2008
Notice the US is not part of the discussion?
Analysis of: Glaxo Seeks Guidance From Health Systems | online.wsj.com
Author: GLG Expert Contributor
GSK is discussing drug development with European countries and not the US. Implications???
July 10, 2008
Medicare fee cuts: Saved by someone who may appreciate the significance........
Analysis of: Bill to Block Medicare-Fee Cuts | online.wsj.com
Author: GLG Expert Contributor
Medicare will not cut physicians fees but will cut payments in HMO driven Medicare "advantage" plans. This means that the republicans will be unable to "feather the nest" of their insurer friends!
July 9, 2008
Further evidence that government intervention is around the corner
Analysis of: Pricey Drugs Put Squeeze on Doctors | online.wsj.com
Author: GLG Expert Contributor
Chemotherapy drugs are so costly that not only are the patients unable to pay co-pays, but oncologists are laying out hundreds of thousands of dollars with only a promise they will be reimbursed.
July 8, 2008
What ever happens I can assure you the Doctors will be f........
Analysis of: Clash on Preventing Cut to Doctor Payments | online.wsj.com
Author: GLG Expert Contributor
11% drop in physician re-imbursement vs HMO sponsored Medicare "advantage" programs. Who will win out?
July 7, 2008
Cost vs Efficacy: A conundrum for insurers, physicians and patients.
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Expert Contributor
Extraordinarily expensive Avastin makes all think twice before using, due to ?? efficacy data as well as questions re: quality of life v survival benefits.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 582

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637